Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?

Xavier Leleu · Francesca Gay · Anne Flament · Kim Allcott · Michel Delforge

Received: 4 October 2017 / Accepted: 20 November 2017 / Published online: 27 December 2017
© The Author(s) 2017. This article is an open access publication

Abstract
Although immunomodulatory drugs, alkylating agents, corticosteroids, protease inhibitors, and therapeutic monoclonal antibodies improve multiple myeloma outcomes, treatment burden is still an issue. Neutropenia is a known complication of cytotoxic cancer therapy and is often associated with infections; it is an important consideration in myeloma given the fact that patients often have a weakened immune system. The risk of febrile neutropenia increases with severe and persisting neutropenia. Recombinant granulocyte colony-stimulating factors (G-CSFs) are commonly used to reduce the incidence, duration, and severity of febrile neutropenia. Here, we review the risk and management of neutropenia associated with new and commonly used anti-myeloma agents. Few papers report the use of G-CSF in patients with multiple myeloma receiving anti-cancer treatments, and fewer describe whether G-CSF was beneficial. None of the identified studies reported G-CSF primary prophylaxis. Further studies are warranted to evaluate the need for G-CSF prophylaxis in multiple myeloma. Prophylaxis may be particularly useful in patients at high risk of prolonged severe neutropenia.

Keywords
Multiple myeloma · Neutropenia · Granulocyte colony-stimulating factors · G-CSF

Introduction
Neutropenia is a recognized complication of cytotoxic cancer therapy. Prolonged severe neutropenia increases the risk of serious infections and of febrile neutropenia, which can themselves be life-threatening. In addition, these conditions can lead to dose modifications or delays, which in turn reduce treatment efficacy [1, 2]. As well as having a significant impact on patients’ well-being, febrile neutropenia places a considerable burden on hospital resources, with affected individuals frequently requiring immediate inpatient admission and antibiotic treatment [3].

An understanding of the neutropenia risk associated with multiple myeloma (MM) treatment is particularly important, given the immunodeficiencies caused by the impact of the disease on B cells, T cells, dendritic cells, and natural killer cells [4]. MM is characterized by proliferation of a clonal population of monotypic plasma cells that differentiate from normal B cells within the bone marrow and produce large amounts of immunoglobulin (M-protein), immunoglobulin (Ig) fragments, or light chains [5]. The abnormal expansion of plasma cells disrupts immune homeostasis, which can in turn lead to neutropenia, hypogammaglobulinaemia, and impaired lymphocyte function, all of which increase susceptibility to infection [6]. MM also affects numerous other organs, either directly (e.g. through accumulation of M-protein in the kidneys) or indirectly (e.g. if bone lesions lead to vertebral collapse in the thorax, this can lead to respiratory problems), which predisposes patients to infection [4]. Furthermore, patients with MM are often elderly and can have comorbidities; both factors can be associated with a weakened immune system [7, 8]. In addition, patients frequently receive multiple, and often long, rounds of treatment with regimens that include...
dexamethasone, which can result in impaired immunity and hyperglycaemia, which in turn increase the risk of infection [4]; indeed, infection is the most frequent cause of death in patients with MM [4].

Antibiotic prophylaxis can prevent infections and reduce mortality in patients receiving cytotoxic therapy [9]; however, most studies of antibiotic efficacy in this setting have been limited to haematological cancers, and the prophylactic use of these agents has raised concerns regarding the development of antibiotic resistance [7, 9]. Therefore, the Infectious Diseases Society of America currently limits its recommendation to the use of quinolones in patients predicted to have infections during the first 2 months of chemotherapy [11]. However, studies suggest that patients with MM are at high risk of neutropenia and febrile neutropenia by stimulating neutrophil maturation and production in the bone marrow. Studies suggest that patients with MM are at high risk of infections during the first 2 months of chemotherapy [11]. Although G-CSF administration will not be effective in reducing the risk of infection if the cause of neutropenia is independent of the G-CSF pathway, or if the mechanism by which the drug increases the risk of infections is not related to neutropenia (such as in the case of dexamethasone), appropriate use of G-CSF prophylaxis can be particularly important to reduce the risk related to a low neutrophil count.

Given the high risk of infection in patients with MM, the immune toxicity of many of the agents used to treat the disease and the various mechanisms by which these agents reduce neutrophil count, we wished to gain a better understanding of the incidence of neutropenia in the treatment of MM and the use of G-CSF prophylaxis. Therefore, we reviewed the literature, with a focus on common standard regimens and important new agents.

**Neutropenia associated with commonly used regimens in MM**

To assess the risk and management of neutropenia associated with new and commonly used anti-myeloma agents, we searched the literature (titles, abstracts, and keywords) in February 2016 for phase 3 clinical trials or observational studies that reported neutropenia-related outcomes in patients with MM. We did not consider studies that were investigating the efficacy of stem cell transplantation (SCT) because for these studies, the main reported G-CSF-related outcomes were mobilization and neutrophil engraftment. Key studies on the newest regimens that were published after February 2016 were selected by authors for inclusion.

Although grade 3–4 neutropenia is a recognized complication of lenalidomide and pomalidomide treatment [12, 13], our literature search revealed that it is widespread in patients with MM, with an incidence of over 10% reported for 28 different regimens (Table 1). Neutropenia rates reported below reflect the incidence of grade 3 or 4 events.

**Neutropenia with current anti-myeloma regimens**

**Bortezomib–dexamethasone-based regimens**

A bortezomib–dexamethasone (VD) backbone is still widely used at first line for transplant-eligible patients; however, we found relatively few reports of neutropenia with VD-based triplet combinations. Neutropenia rates of 25% or lower were reported in two observational studies and a phase 3 study of patients receiving lenalidomide with VD; similar neutropenia rates were reported in the majority of studies investigating the addition of doxorubicin to VD (all phase 3 clinical trials) and the majority of phase 3 and observational studies in which thalidomide was added to VD [14–22]. In contrast, two of three phase 3 studies of combinations of cyclophosphamide and VD reported that neutropenia affected 40% of patients; neutropenia was also reported in 50% of participants in an observational study of the same regimen [17, 21, 23]. Only two studies reported G-CSF use in patients receiving a VD-based triplet regimen. In the retrospective observational study of lenalidomide with VD by Jimenez-Zepeda et al., 8 of 30 (3.75%) patients were administered G-CSF, and in a clinical trial by Palumbo et al. investigating doxorubicin with VD, 15 of 64 patients (4.3%) received G-CSF [15, 22].

**Immunomodulatory drug-based regimens**

Lenalidomide–dexamethasone (RD)-containing regimens are among the most commonly used in patients with MM but are also among those with the highest reported incidences of neutropenia (Fig. 1). Lenalidomide can be combined with low- or high-dose dexamethasone; for simplicity, we included RD-based regimens regardless of the dose of dexamethasone used. Although RD was initially reported as low risk based on the pivotal phase 3 trial [8, 24], we found other phase 3 and observational studies reporting higher incidences of neutropenia with RD (up to 61%) (Fig. 1) [14, 25–46]. Infection rates were moderate compared with neutropenia rates (Table 2), reaching 37% in the expanded access study by Sun et al. [45]; however, rates of febrile neutropenia were low (<1–6%, Table 2).

When reported, G-CSF use was between 22 and 54% and was initiated after the manifestation of neutropenia. In a phase 3 trial by Dimopoulos et al., G-CSF was used to manage neutropenia in 22% of patients. In the same study, the neutropenia rate was 30%, the infection rate was 11%, and dose...
Table 1 Neutropenia rates by regimen

| Regimen          | Range of reported grade 3 and 4 neutropenia, % | Number of studies |
|------------------|-----------------------------------------------|-------------------|
| Thalidomide      | 0 ≤ 5                                         | 1                 |
| CTD              | 0 ≤ 5                                         | 1                 |
| VT               | 0 ≤ 5                                         | 1                 |
| VP               | 0 ≤ 5                                         | 1                 |
| Bortezomib       | 0 ≤ 5                                         | 2                 |
|                  | > 5 ≤ 10                                      | 1                 |
|                  | > 10 ≤ 25                                     | 7                 |
|                  | > 25 ≤ 50                                     | 0                 |
| VD               | 0 ≤ 5                                         | 2                 |
|                  | > 5 ≤ 10                                      | 1                 |
|                  | > 10 ≤ 25                                     | 2                 |
| VTD              | 0 ≤ 5                                         | 2                 |
|                  | > 10 ≤ 25                                     | 2                 |
|                  | > 25 ≤ 50                                     | 1                 |
| Bortezomib-based | > 5 ≤ 10                                      | 1                 |
|                  | > 10 ≤ 25                                     | 2                 |
|                  | > 25 ≤ 50                                     | 1                 |
| Dexamethasone    | 0 ≤ 5                                         | 5                 |
|                  | > 10 ≤ 25                                     | 1                 |
| Lenalidomide maintenance | > 5 ≤ 10                                     | 2                 |
|                  | > 10 ≤ 25                                     | 2                 |
|                  | > 25 ≤ 50                                     | 1                 |
| RD               | 0 ≤ 5                                         | 1                 |
|                  | > 5 ≤ 10                                      | 1                 |
|                  | > 10 ≤ 25                                     | 11                |
|                  | > 25 ≤ 50                                     | 9                 |
|                  | > 50 ≤ 75                                     | 2                 |
| RP maintenance   | > 5 ≤ 10                                      | 1                 |
| RVD              | > 5 ≤ 10                                      | 1                 |
|                  | > 10 ≤ 25                                     | 1                 |
| Lenalidomide-based | > 10 ≤ 25                                     | 2                 |
|                  | > 25 ≤ 50                                     | 5                 |
| ERD              | > 25 ≤ 50                                     | 1                 |
| MP               | > 5 ≤ 10                                      | 1                 |
|                  | > 25 ≤ 50                                     | 2                 |
| MPT              | > 10 ≤ 25                                     | 1                 |
|                  | > 25 ≤ 50                                     | 1                 |
| PAN-BTZ-Dex      | > 25 ≤ 50                                     | 1                 |
| VCD              | > 10 ≤ 25                                     | 1                 |
|                  | > 25 ≤ 50                                     | 2                 |
| VMP              | > 10 ≤ 25                                     | 1                 |
|                  | > 25 ≤ 50                                     | 2                 |
| VMPT             | > 25 ≤ 50                                     | 1                 |
| PAD              | > 10 ≤ 25                                     | 2                 |
| RCD consolidation | > 10 ≤ 25                                     | 1                 |
| PD               | > 25 ≤ 50                                     | 4                 |
| PVD              | > 25 ≤ 50                                     | 1                 |

Table 1 (continued)

| Regimen          | Range of reported grade 3 and 4 neutropenia, % | Number of studies |
|------------------|-----------------------------------------------|-------------------|
| IRD              | > 10 ≤ 25                                     | 1                 |
| Vorinostat + bortezomib | > 10 ≤ 25                                    | 1                 |
| KRD              | > 25 ≤ 50                                     | 1                 |
| MPR              | > 50 ≤ 75                                     | 1                 |
|                 | > 75-100                                      | 1                 |
| CHOP             | > 50 ≤ 75                                     | 1                 |
| HD-M             | > 50 ≤ 75                                     | 1                 |
|                 | > 75-100                                      | 3                 |
| VTD-PACE         | > 50 ≤ 75                                     | 1                 |
|                 | > 75-100                                      | 1                 |
| PACE             | > 75-100                                      | 1                 |

CHOP cyclophosphamide/doxorubicin/vincristine/prednisone, CTD cyclophosphamide/thalidomide/dexamethasone, ERD elotuzumab/lenalidomide/dexamethasone, HD-M high-dose melphalan, IRD ixazomib/lenalidomide/dexamethasone, KRD carfilzomib/lenalidomide/dexamethasone, MPR melphalan/prednisone, MPR melphalan/prednisone/lenalidomide, MPT melphalan/prednisone/thalidomide, PACE cisplatin/doxorubicin/cyclophosphamide/etoposide, PAD bortezomib/doxorubicin/dexamethasone, PD pomalidomide/dexamethasone, PVD pomalidomide/bortezomib/dexamethasone, PAN-BTZ-Dex panobinostat/bortezomib/dexamethasone, RCD lenalidomide/cyclophosphamide/dexamethasone, RD lenalidomide/dexamethasone, RCP lenalidomide/thalidomide/temafadone, RP lenalidomide/prednisone, RVD lenalidomide/bortezomib/dexamethasone, VCD bortezomib/cyclophosphamide/dexamethasone, VD bortezomib/dexamethasone, VMP bortezomib/melphalan/prednisone, VMPT bortezomib/melphalan/prednisone/thalidomide, VP bortezomib/prednisone, VT bortezomib/thalidomide, VTD bortezomib/thalidomide/dexamethasone, VTD-PACE bortezomib/thalidomide/dexamethasone/cisplatin/doxorubicin/cyclophosphamide/etoposide

Fouquet et al., 34% of patients had a dose reduction owing to any adverse event (AE) were recorded in 76% of patients [41]. In a similar phase 3 study by Weber et al., in which 41% of patients experienced neutropenia and 22% had an infection, 34% received reactive G-CSF and dose reductions were required in 77% of participants (neutropenia was mentioned as a primary reason for dose reduction) [46]. In the observational study by Leleu et al., 31% of patients experienced neutropenia and 23% received reactive G-CSF, which the authors noted was probably reactive. Dose reductions and interruptions with neutropenia as the primary cause were rare [42]. In the retrospective analysis of patients on the MM-016 extended access programme by Sun et al., intermittent G-CSF (6 doses per cycle) was used reactively in 49% of patients and as secondary prophylaxis in 5%. Infection rates remained high, but patients receiving G-CSF were able to receive RD for longer than those who did not receive G-CSF, which appeared to lead to improved response rates [45]. In the French observational study by Fouquet et al., 34% of patients had a dose reduction owing
to either neutropenia or thrombocytopenia [32]; in the Greek study by Katodritou et al., neutropenia was the most common AE leading to treatment discontinuation (7%) [60]. G-CSF use was not reported in either publication.

Pomalidomide with dexamethasone has been approved for patients who have received at least two previous therapies including bortezomib and lenalidomide [61]. Phase 3 studies suggest that the risk of grade 3 or 4 neutropenia (approximately 50%) is slightly higher with pomalidomide than with lenalidomide (Fig. 1) [53, 56]. Subsequent analysis of one study found that neutropenia was the most common AE leading to dose reductions and interruptions (4.7 and 19.4% of patients, respectively) [62]. Although San Miguel et al. noted that neutropenia did not necessarily translate into infection, the data showed that in the active arm, 30% of patients experienced infection (compared with 24% in the control arm) and 10% experienced grade 3 or 4 febrile neutropenia, which was much higher than the incidence in the control arm (< 1%) [56]. Although San Miguel et al. noted that neutropenia did not necessarily translate into infection, the data showed that in the active arm, 30% of patients experienced infection (compared with 24% in the control arm) and 10% experienced grade 3 or 4 febrile neutropenia, which was much higher than the incidence in the control arm (< 1%) [56].

It should be noted that pomalidomide has so far been studied in heavily pre-treated patients who are therefore likely to have advanced disease and reduced bone marrow function; in the pivotal phase 3 study, the median number of previous treatments was five, and over 90% of patients had received more than two previous treatments [56]. Neutropenia rates in patients using pomalidomide at earlier lines of therapy may therefore be lower than the rates reported in the phase 3 study. Two small observational studies suggest that the real-world incidence of neutropenia with this regimen may be slightly lower. However, despite the lower rates of neutropenia, in the observational study by Maciocia et al., 11% of patients had grade 3 or 4 neutropenic sepsis and Miles et al. reported sepsis requiring hospital admission in 24% of patients [54, 55]. Additional data in a larger population would be needed to confirm these findings.

In common with lenalidomide, the phase 3 studies reported that dose interruptions and dose reductions with pomalidomide were common (67 and 66%, and 27 and 22% for interruptions and reductions, respectively, in the two studies) [53, 56]. G-CSF use was reported only by San Miguel et al. and was used in 43% of patients [56].

Melphalan–prednisone-based regimens

All studies of melphalan–prednisone-based regimens were clinical trials; we did not find any observational studies reporting neutropenia rates. Melphalan and prednisone (MP) alone were associated with a risk of neutropenia of less than 10% in one trial and a higher risk (37–38%) in two trials (Table 2) [47–49]. However, the combination of melphalan, prednisone, and lenalidomide (MPR) was consistently associated with neutropenia in over half of patients [49, 50]. In contrast, although combining melphalan and prednisone with thalidomide (MPT) or bortezomib (VMP) was also associated with neutropenia incidences of over 20%, there were no reports of these agents causing neutropenia in more than 50% of patients [18, 28, 47, 48, 51]. These differences are illustrated by the recently published head-to-head study of MPR versus MPT, which found that the incidence of neutropenia with MPR was more than twice that with MPT [63]. This indicates
Table 2  Infection rates in regimens associated with high levels of neutropenia in selected regimens of interest

| Author/date          | Regimen       | Grade 3 and 4 neutropenia, % | Grade 3 and 4 infection, % | Febrile neutropenia, % |
|----------------------|---------------|------------------------------|----------------------------|------------------------|
| Bortezomib–dexamethasone-based |
| Jimenez-Zepeda et al. [15] | RVD          | 7                            | 26                         | NR                     |
| Durie et al. [14]    | RVD          | 19                           | NR                         | NR                     |
| Garcia-Sanchez et al. [16] | VTD      | 9                            | NR                         | NR                     |
| Takashima et al. [19] | VTD          | 17                           | 21 (not specified if grade 3–4) | NR                    |
| Wu et al. [20]       | VTD          | 43.3 (VTD)                   | NR                         | NR                     |
|                      |              | 40 (improved VTD)            |                            |                        |
| Moreau et al. [17]   | VTD          | 12                           | NR                         | NR                     |
| Niesvizky et al. [18] | VTD        | 3                            | NR                         | NR                     |
| Palumbo et al. [22]  | PAD          | 36                           | 15 (serious infection)     | 3                      |
| Mai et al. [21]      | PAD          | 11                           | 13 (serious infection)     | NR                     |
| Moreau et al. [17]   | VCD          | 23                           | NR                         | NR                     |
| Mai et al. [21]      | VCD          | 35                           | 11 (serious infection)     | NR                     |
| Kusano et al. [23]   | VCD          | 50                           | NR                         | NR                     |
| Melphalan–prednisone-based |
| Hulin et al. [47]    | MP           | 9                            | NR                         | NR                     |
| Richardson et al. [48] | MP         | 38                           | NR                         | 4                      |
| Palumbo et al. [49]  | MP           | 37                           | 7                          | 0                      |
| Palumbo et al. [50]  | MPR          | 52                           | 0.8                        | NR                     |
| Palumbo et al. [49]  | MPR plus lenalidomide maintenance | 67 grade 3 and 35 grade 4 | 11 | 7 |
| Hulin et al. [47]    | MPR          | 64 grade 3 and 32 grade 4    | 15 | 2 |
| Facon et al. [28]    | MPT          | 45                           | 17                         | 3                      |
| Niesvizky et al. [18] | VMP        | 21                           | NR                         | NR                     |
| Richardson et al. [48] | VMP      | 40                           | NR                         | 3                      |
| Palumbo et al. [51]  | VMP          | 28                           | 9                          | 2                      |
| Lenalidomide–dexamethasone-based |
| Dimopoulos et al. [27] | RD (low dose) | 3                            | NR                         | NR                     |
| Dimopoulos et al. [27] | RD (intermediate dose) | 23                      | NR                         | NR                     |
| Mookerjee et al. [35] | RD          | 11                           | NR                         | NR                     |
| Firatli Tuglular et al. [30] | RD     | 10                           | NR                         | NR                     |
| Durie [14]           | RD           | 21                           | NR                         | NR                     |
| Zonder et al. [39]   | RD           | 21                           | 16                         | NR                     |
| Bekscak et al. [25]  | RD           | 16                           | NR                         | 4                      |
| Tosi et al. [38]     | RD           | 35                           | 15                         | NR                     |
| Fouquet et al. [32]  | RD           | 16                           | NR                         | NR                     |
| Family et al. [29]   | RD (4 cycles)| 24                           | 3.8                        |                        |
| Huang et al. [34]    | RD           | 20                           | 9                          | NR                     |
| Dimopoulos et al. [26] | RD        | 17                           | 0                          |                        |
| Firatli Tuglular et al. [31] | RD     | 24                           | 11                         | NR                     |
| Gay et al. [52]      | RD           | 24                           | 6                          | NR                     |
| Weber et al. [46]    | RD           | 41                           | 22                         | 3                      |
| Dimopoulos et al. [41] | RD        | 30                           | 11                         | 3                      |
| Geraldes et al. [33] | RD           | 35                           | 25                         | NR                     |
| Schwarzer et al. [37] | RD         | 32                           | 11                         | <1                     |
| Facon et al. [28]    | RD           | 28                           | 29                         | 1                      |
| Leleu et al. [42]    | RD           | 31                           | NR                         | 3                      |
| Stewart et al. [44]  | RD           | 27                           | NR                         | NR                     |
| Lomial et al. [43]   | RD           | 44                           | NR                         | NR                     |
| Sun et al. [45]      | RD           | 61                           | 37                         | NR                     |
| Alegre et al. [40]   | RD           | 51                           | NR                         | 6                      |
| Durie et al. [14]    | RVD          | 19                           | NR                         | NR                     |
| Jimenez-Zepeda et al. [15] | RVD | 7                            | 26                         | NR                     |
that the risk of neutropenia is affected by the type and the number of agents in a regimen, and highlights the importance of considering strategies to reduce the neutropenic risk.

The patient population should also be considered when interpreting these data: MP-based combinations are usually recommended for patients not eligible for SCT. Such patients are typically elderly with poor performance status, both of which are recognized risk factors for neutropenia [7]. Indeed, all five studies of VMP and MPT were in patients who were elderly or not eligible for transplantation or high-dose therapy. Whereas a study of MPR in transplant-eligible patients reported a neutropenia rate of 52% [50], neutropenia rates were approximately 100% (64–67% grade 3 and 32–35% grade 4) in the study of transplant-ineligible patients [49]. In clinical practice, VMP is the most commonly used melphalan-containing regimen and MPR is not currently recommended by some guidelines [64].

Despite the high rates of neutropenia seen with these triplets, few patients experienced infections, and rates of febrile neutropenia were low (Table 2). Notably, Hulin et al. found that in their trial of MPT in elderly patients, neutropenia did not appear to result in more frequent serious infection [47]. This is particularly encouraging, given that infection can be more serious in elderly patients than in younger individuals. The low rate of infection compared with RD regimens could reflect the tolerability profile of prednisone, which differs from that of dexamethasone. Moreover, real-world infection rates may differ from those seen in these phase 3 studies; the selection criteria for clinical trials might exclude the frailest patients who could be most likely to experience infections.

Hulin et al. reported that thalidomide increased the requirement for dose reductions (for any reason) owing to AEs when added to MP (20 vs 3%) [47]. Richardson et al. was the only paper describing an MP study that reported the number of dose reductions due to neutropenia. In this study, bortezomib and melphalan were reduced in 2 and 5% of patients, respectively, in the VMP arm and melphalan was reduced in 7% of patients in the MP arm [48]. In the same study, G-CSF was used in 21 and 23% of patients, respectively [48]. However, the publication did not specify whether G-CSF was used prophylactically or reactively, so it is difficult to draw any conclusions regarding the relationship between its use and rates of neutropenia and infection or dose maintenance.

### Neutropenia associated with newer treatment regimens

In the past 2 years, several new therapies have been approved for the treatment of patients with MM. Panobinostat in combination with bortezomib and dexamethasone has been approved for patients with relapsing and/or refractory multiple myeloma (RRMM) who have received at least two previous regimens including bortezomib and an immunomodulatory agent [65]. In the phase 3 study, neutropenia was reported in 35% of patients. However, the evidence base for this agent is still small [66]. Carfilzomib has recently been approved in combination with lenalidomide and dexamethasone, and with dexamethasone alone, for patients with RRMM [67]. Neutropenia of grade 3 or higher has been reported in the triplet combination [44], but this is likely to reflect the AE profile of lenalidomide, rather than that of carfilzomib (the incidence was 30% with carfilzomib vs 27% with lenalidomide and dexamethasone). In a double-blind, placebo-controlled phase 3 study conducted to assess progression-free survival in patients with MM receiving lenalidomide in combination with dexamethasone and ixazomib, neutropenia was observed in 23% of patients receiving active treatment and 24% of patients receiving placebo [68]. In a phase 3 study comparing lenalidomide with

**Table 2 (continued)**

| Author/date | Regimen | Grade 3 and 4 neutropenia, % | Grade 3 and 4 infection, % | Febrile neutropenia, % |
|-------------|---------|-----------------------------|---------------------------|------------------------|
| Dimopoulos et al. [53] | PD | 50 | NR | NR |
| Maciocia et al. [54] | PD | 35 | Neutropenic sepsis, 11 | NR |
| Miles and Wells [55] | PD | 26 | Sepsis requiring admission, 24 | NR |
| San Miguel et al. [56] | PD | 48 | | 10 |
| High-dose melphalan | | | | |
| Cook et al. [57] | HD-M plus salvage ASCT | 75 | NR | NR |
| Palumbo et al. [58] | HD-M | 77 | 40 | 17 |
| Palumbo et al. [50] | HD-M | 94 | 16.3 (includes febrile neutropenia) | NR |
| Gay et al. [59] | HD-M | 80 | 19 | NR |

ASCT autologous stem cell transplantation, HD-M high-dose melphalan, MP melphalan/prednisone, MPR melphalan/prednisone/lenalidomide, MPT melphalan/prednisone/thalidomide, NR not reported, PD pomalidomide/dexamethasone, RD lenalidomide/dexamethasone, RVD lenalidomide/bortezomib/dexamethasone, VMP bortezomib/melphalan/prednisone
dexamethasone and daratumumab with lenalidomide and dexamethasone alone, neutropenia occurred more frequently in the daratumumab group (52%) than in the control group (37%). Corresponding figures for febrile neutropenia were 5.7% (all of grade 3 or 4) and 2.5% (all of grade 3 or 4), respectively [69]. The incidence of neutropenia was lower in patients treated with VD–daratumumab than in those receiving VD alone in a phase 3 randomized trial: 12.8 and 4.2%, respectively [70]. In another phase 3 trial comparing eloctozumab plus lenalidomide and dexamethasone with lenalidomide plus dexamethasone alone (control group), neutropenia occurred at a lower rate in the eloctozumab group (34%) than in the control group (44%) [71].

Regimens associated with a very high incidence of neutropenia

We found several regimens associated with a very high incidence (76–100%) of neutropenia. High-dose melphalan (HD-M) as part of SCT is a standard treatment approach in transplant-eligible patients and was reported to be associated with neutropenia in five publications [50, 57–59]. Infection rates were high in the report of the phase 3 trial by Palumbo et al., despite prophylactic G-CSF administration (40% of patients had an infection and 17% had febrile neutropenia) [58]; however, considering the high rates of neutropenia, infection rates were relatively low in the other studies (Table 2), such as in Palumbo et al.’s report of their HD-M trial (16%) [50]. However, in both studies, patients were younger than 65 years of age; the risk–benefit profile of this regimen is likely to be different in elderly patients. Despite the high toxicity associated with this treatment approach, SCT remains the optimal treatment for patients with early-stage disease [59].

Other regimens associated with very high levels of neutropenia were bortezomib, thalidomide, dexamethasone and cisplatin, doxorubicin, cyclophosphamide and etoposide (VTD-PACE) in patients with NDMM, and cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) in patients with RRMM, which resulted in neutropenia rates of 79 and 83% and febrile neutropenia rates of 26 and 33%, respectively [72, 73].

Pegfilgrastim in MM

Over two decades ago, filgrastim, the first daily G-CSF, was approved for reducing the risk of febrile neutropenia in patients receiving cytotoxic chemotherapy for cancer [74]. Since then, lenograstim has also been developed as a daily G-CSF [75]. These agents are also indicated for mobilizing peripheral blood progenitor cells and for reducing the duration of neutropenia in patients undergoing bone marrow transplantation [74, 75]. In 2002, the first long-acting G-CSF, pegfilgrastim, was approved in Europe for reducing the duration of neutropenia and the incidence of febrile neutropenia in adults receiving cytotoxic chemotherapy for cancer [76]. Pegfilgrastim may be preferred over filgrastim by patients and physicians owing to its reduced clearance, which means that only one dose is required per chemotherapy cycle [76]. Pegfilgrastim has also been shown to be more effective than filgrastim at reducing neutropenia and febrile neutropenia in clinical practice [77, 78]. More recently (in 2013), lipegfilgrastim, another long-acting G-CSF, became available for febrile neutropenia prophylaxis [79].

To understand whether long-acting G-CSFs are used in the management of neutropenia in patients with MM, we performed an additional search for articles reporting pegfilgrastim use in patients with this disease. Our search was limited to articles published between 1 January 2013 and 17 February 2016 to capture current clinical practice. Few studies published in the past 3 years reported using pegfilgrastim in MM (N = 16) (Supplementary Table 1).

Pegfilgrastim for neutropenia prophylaxis

Most studies investigated the use of pegfilgrastim with SCT to promote neutrophil engraftment; however, we found five reports of pegfilgrastim being used for neutropenia prophylaxis in patients with MM. Two of these studies used pegfilgrastim in lenalidomide-based regimens. An observational study of patients with RRMM found that pegfilgrastim was given to 8% of patients receiving RD [42]. Daily G-CSF was used more frequently (16% of patients). The authors stated that G-CSF use was likely to have been reactive, not prophylactic.

Pegfilgrastim was used as primary prophylaxis in a dose-escalation study of lenalidomide, doxorubicin, and dexamethasone for patients with RRMM [80]. Pegfilgrastim allowed the dose of lenalidomide to be raised from 15 to 25 mg, in combination with doxorubicin 9 mg/m² and dexamethasone 40 mg. At this final dose, the maximum tolerated dose threshold of 33% or higher incidence of dose-limiting toxicity was still not reached; 48% of patients experienced grade 3 or 4 neutropenia and 23% required dose reductions. The increased dose of lenalidomide facilitated by the addition of pegfilgrastim allowed a much larger proportion of patients to achieve a very good partial response or complete response, compared with the lower dose level (74 vs 23%).

Pegfilgrastim primary prophylaxis has been reported in a phase 1 study of hydroxychloroquine with cyclophosphamide, dexamethasone, and rapamycin in patients with RRMM. Of 15 patients evaluated for toxicity, one experienced grade 4 neutropenia [81]. One retrospective study compared pegfilgrastim and filgrastim primary prophylaxis for reducing neutropenia following SCT. The analysis found no statistically
significant differences in median time to leukocyte recovery or duration of febrile neutropenia [82]. The authors concluded that the main difference between filgrastim and its pegylated form is the more convenient formulation of pegfilgrastim as a single fixed dose than as multiple daily administrations.

A prospective cohort study in which patients with advanced MM were treated with reactive filgrastim during their first course of chemotherapy and with pegfilgrastim prophylaxis during their second course reported that pegfilgrastim appeared to reduce the incidence of neutropenia to a greater extent than did daily injections of filgrastim [83].

**Tolerability of pegfilgrastim**

Looking across all studies of pegfilgrastim, the agent appeared to be generally well tolerated. The prospective cohort study of sequential filgrastim and pegfilgrastim treatment reported that the main AEs following pegfilgrastim administration were mild fever and bone pain, which were experienced by 12% of patients [83]. In the observational IMPACT study, no adverse drug reactions to any G-CSF were reported [42]. Another study assessing pegfilgrastim with and without cyclophosphamide reported no hospitalizations due to toxicity in the pegfilgrastim group [84]. When pegfilgrastim was administered 6 days after a chemotherapy regimen of lenalidomide, doxorubicin, and dexamethasone, no treatment-related mortality was reported, and rates of febrile neutropenia and venous thromboembolism were less than 10% [85–87]. One phase 1 study assessed escalating doses of melphalan and carfilzomib with a constant pegfilgrastim dose. Although efficacy and safety data are not specific to pegfilgrastim, the authors did report infection in 58% of patients, febrile neutropenia in 33%, and pneumonia, bacteraemia and urinary tract infection each in 8% of patients [88]. A similar phase 1 dose-escalation study reported four episodes of thrombocytopenia, one episode of neutropenia and five episodes of lymphopenia, all grade 4 in severity, in a population of 15 patients [81]. Although these data were more specific for the chemotherapy treatment of hydroxychloroquine (at ascending doses) along with cyclophosphamide and rapamycin, patients were also treated with pegfilgrastim on day 6.

**Characteristics of patients receiving pegfilgrastim**

In the observational study by Leleu et al. of patients with RRMM receiving RD, those who received pegfilgrastim were more likely to have International Staging System stage III at diagnosis, more than four previous treatments and more comorbidities than those who were given daily G-CSFs [42]. They were also more likely to be younger and to be receiving the recommended 25 mg dose of lenalidomide [42]. This suggests that pegfilgrastim may be reserved for patients with a high risk of neutropenia. Aside from that publication, we did not find any reports of the baseline characteristics of patients with MM who were given pegfilgrastim.

However, studies reporting pegfilgrastim use in patients with various haematological malignancies including MM, but that do not report MM data separately, do give details of the baseline characteristics of patients prescribed pegfilgrastim in real-world practice. Several single-centre studies comparing patients who received daily G-CSF with those receiving pegfilgrastim for reducing time to neutrophil engraftment found no differences between the two groups in terms of the baseline characteristics of the patients, although non-significant differences in patient age were seen [89–91]. In Carlino et al., patients receiving pegfilgrastim had a median age of 51 years, compared with 62 years in those receiving daily G-CSFs. Herbert et al. reported median ages of 50 and 56 years for those receiving pegfilgrastim and filgrastim, respectively. Another single-centre study comparing these agents for neutrophil engraftment found that patients given pegfilgrastim were younger than those receiving filgrastim (median age 46 vs 54 years; \( P = 0.05 \)) [92]. This pattern of treatment could be due to a tendency to treat younger patients with more aggressive or intensive treatment than older patients.

**Implications for clinical practice**

Together, the studies described above indicate that G-CSF is not regularly used prophylactically in patients with MM. The European Organisation for Research and Treatment of Cancer recommends G-CSF prophylaxis for patients undergoing a chemotherapy regimen with a high (≥20%) risk of febrile neutropenia and for patients receiving a chemotherapy regimen with an intermediate (10–20%) risk of febrile neutropenia if they have additional risk factors [7]. In patients with MM, it has been suggested that G-CSF prophylaxis should be administered to those who are undergoing treatment regimens associated with a neutropenia rate of over 50% (those that combine lenalidomide with doxorubicin and dexamethasone, with MP or with cyclophosphamide and dexamethasone). G-CSF prophylaxis is also advised for patients with MM who have additional risk factors (e.g. those aged > 65 years, frail patients and patients with comorbidities) who are receiving a regimen associated with an intermediate risk of neutropenia (e.g. triplet regimens containing bortezomib) [8]. It may also be prudent to consider G-CSF use in patients with aggressive disease to help to avoid the need for treatment delays that may otherwise be required if neutropenia occurs [3]. This can be of particular importance during the first cycles of treatment (at diagnosis and at relapse), when the risk of cytopenia and of infections related to the high tumour burden can be higher. In the relapse setting, the risk of infections may also be particularly high (see...
Such as the alkylating agent melphalan [93], target rapidly proliferating cells and therefore kill myeloid cells as well as malignant cells. However, agents with different mechanisms of action, such as immunomodulatory drugs and monoclonal antibodies, also induce neutropenia. Lenalidomide-induced neutropenia is thought to be associated with the loss of the transcription factor PU.1, which is required for granulopoiesis and neutrophil maturation [20]. The monoclonal antibody daratumumab has recently been approved for use as a monotherapy in Europe and as a monotherapy and in combination with RD or VD in the USA. Neutropenia has been reported for all regimens, but particularly when daratumumab is combined with RD. The mechanism is unclear, but the target of daratumumab, CD38, is known to regulate neutrophil chemotaxis and is present on myeloid stem cells [94, 95]. Neutropenia has also been associated with the monoclonal antibody rituximab; in this setting, it has a late onset and is thought to correlate with B cell recovery following treatment. Rapidly expanding B cells consume the chemokine stromal cell-derived factor 1, which is required for neutrophil egress from the bone marrow [96]. This illustrates the variety of mechanisms by which drugs can induce neutropenia.

As noted above, few papers described G-CSF use in studies of anti-cancer agents in MM, and fewer still evaluated whether or not G-CSF use had a beneficial effect. Further research is required in order to understand how to optimize G-CSF prophylaxis according to the anti-cancer agent used.

**Discussion and conclusions**

The pathophysiology of MM, and its tendency to occur in elderly patients, means that neutropenia (and potentially infection) is a common occurrence. MM is a long-lasting disease that requires several treatment courses. Patients may have pre-existing hypogammaglobulinaemia and lymphopenia, in addition to neutrophil destruction by anti-cancer agents. Physicians need to be aware of the incidence and causes of low neutrophil counts, in addition to other risk factors for infection, in order to understand the risk for each of their patients and to manage this risk effectively.

Although infections and febrile neutropenia are lower than may be expected, we found a lack of data on antibiotic prophylaxis in the identified studies, so it is unclear to what extent antibiotics may be influencing infection rates. One of the most important factors influencing infection risk is the duration of neutropenia. This is generally short with most of the commonly used outpatient regimens, which may explain the low incidence of infections. Much of the available data are, however, from clinical trials, in which the patients represent a highly selected population with fewer comorbidities than the overall population. Therefore, rates of infection in clinical practice may be expected to be higher than those reported in the trials, particularly in patients who are elderly, in those with comorbidities, those who have very aggressive disease or those who have received multiple lines of therapy. In these patients, preventing neutropenia is particularly important and may help to avoid treatment delays or dose reductions, thus maximizing patient benefit.

Despite the importance of reducing the incidence and duration of neutropenia, few studies report using G-CSF in this patient population, and none of the studies we identified reported primary prophylaxis with G-CSF. Similar inconsistencies in reporting were found by Chan et al. in their analysis of the reporting of supportive care use in clinical trials published between January 2005 and June 2009 [97]. It is therefore difficult to draw conclusions about the potential role of G-CSF in MM. Nevertheless, two studies did report that G-CSF use permitted increased durations of chemotherapy use, which translated into improved response rates.

Further studies are warranted to evaluate the need for G-CSF prophylaxis in MM. If such treatment is required, there are preliminary suggestions that pegfilgrastim may be preferred over daily G-CSFs owing to the single-use formula. Pegfilgrastim may be particularly useful in patients at high risk of prolonged severe neutropenia, owing to the myelotoxicity of the regimen; patient risk factors such as old age, frailty or poor compliance; disease risk factors such as high tumour burden or a combination of all three.

**Acknowledgements** The authors would like to thank Kim Allcott Ph.D. from Oxford PharmaGenesis, Oxford, UK, who provided medical writing support, and Stéphane Gamboni Ph.D. and Sarah Petrig BSc from Amgen (Europe) GmbH for their editorial support. Medical writing support was funded by Amgen (Europe) GmbH.

**Author contributions** All authors made substantial contributions to the conception of the article, were involved with developing the draft of the article and revising it critically for important intellectual content, approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

**Compliance with ethical standards**

**Informed consent** For this type of study, formal consent is not required.
Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Lyman GH (2009) Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Cancer Netw 7(1):99–108. https://doi.org/10.6004/jncn.2009.0009
2. Viscoli C, Varnier O, Machetti M (2005) Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis 40(Suppl 4):S240–S245. https://doi.org/10.1086/427329
3. Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Support Cancer Ther 1(1):23–35. https://doi.org/10.3816/SCT.2003.n.002
4. Nucci M, Anaissie E (2009) Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents. Clin Infect Dis 49(8):1211–1225. https://doi.org/10.1086/605664
5. De Raeve HR, Vanderkerken K (2005) The role of the bone marrow microenvironment in multiple myeloma. Histol Histopathol 20(4):1227–1250. 10.14670/HH-20.1227
6. Pratt G, Goodyear O, Moss P (2007) Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 138(5):563–579. https://doi.org/10.1111/j.1365-2141.2007.06705.x
7. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C, European Organisation for Research and Treatment of Cancer (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32. https://doi.org/10.1016/j.ejca.2010.10.013
8. Palumbo A, Blade J, Boccadoro M, Palladino C, Davies F, Dimopoulos M, Dmoszynska A, Einsele H, Moreau P, Sezer O, Spencer A, Sonneveld P, San Miguel J (2012) How to manage neutropenia in multiple myeloma. Clin Lymphoma Myeloma Leuk 12(1):5–11. https://doi.org/10.1016/j.clml.2011.11.001
9. Gafer-Gvili A, Fraser A, Paul M, Vidal L, Lavrie TA, van de Wetering MD, Kramer LC, Leibovici L (2012) Antibiotic prophylaxis for bacterial infections in aleblinene neutropenic patients following chemotherapy. Cochrane Database Syst Rev 1:CD004386. https://doi.org/10.1002/14651858.CD004386.pub3
10. Freifeld AG, Bow EJ, Sepkowitz KA, Bocch GJ, Ito JJ, Muller CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 52(4):e56–e93
11. Oken MM, Pomeroy C, Weisdorf D, Bennett JM (1996) Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 100(6):624–628. https://doi.org/10.1016/S0002-9343(95)00443-7
12. Bird JM, Owen RG, D'Sa S, Snowden JA, Pratt G, Ashcroft J, Yong K, Cook G, Feyler S, Davies F, Morgan G, Cavenagh J, Low E, Behrens J, Haematology Oncology Task Force of British Committee for Standards in Haematology, UK. Myeloma Forum (2011) Guidelines for the diagnosis and management of multiple myeloma 2011. Br J Haematol 154(1):32–75. https://doi.org/10.1111/j.1365-2411.2011.08573.x
13. Hanaizi Z, Flores B, Hemmings R, Camarero J, Sancho-Lopez A, Salmonson T, Gisselbrecht C, Laane E, Pignatti F (2015) The European Medicines Agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use. Oncologist 20(3):329–334. https://doi.org/10.1634/theoncologist.2014-0073
14. Durie B, Hoering A, Rajkumar SV, Abidi MH, Epstein J, Kahani SP, Thakur MC, Reu FJ, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A (2015) Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (PTS) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777. Blood 126(23):25
15. Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V (2013) Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. Leuk Lymphoma 54(3):555–560. https://doi.org/10.3816/lym-2011.07.19614
16. Garcia-Sanchez R, Gonzalez-Fernandez A, Garcia-Fortes M, Rivas-Luque M, Fernandez-Fernandez A, Cabrera Ruiz F, Campos-Garrigos A, Caparros-Miranda I, Queipo De Llano Temboury MP, Rosell-Mas A, Ruiz-Arredondo JJ (2015) Frontline treatment scheme VTD (bortezomib/thalidomide/dexamethasone) in patients with multiple myeloma transplant candidates at our center. Clin Lymphoma Myeloma Leuk 15(Suppl 3):e168–e169
17. Moreau P, Hulin C, Macro M, Caillot D, Chaletz C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoiffie M, Stoppa AM, Dejoie T, Attal M (2015) Bortezomib, thalidomide and dexamethasone (VTD) is superior to bortezomib, cyclophosphamide and dexamethasone (VCD) prior to autologous stem cell transplantation for patients with de novo multiple myeloma. Results of the prospective IFM 2013-04 trial. Blood 126:393
18. Niesvizky R, Fina RN, Ritkin RM, Gabrial NY, Charu V, Clowney K, Essell J, Gaffar YA, Warr TA, Neuwirth R, Corzo D, Reeves J (2010) Phase 3b UPFRONT study: safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients. Blood 116:393
19. Takashima S, Miyamoto T, Kadowaki M, Ito Y, Aoki T, Takase K, Shima T, Yoshimoto G, Kato K, Muta T, Shirasuki M, Takenaka K, Iwasaki H, Teshima T, Kamimura T, Akashi K (2014) Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. Int J Hematol 100(2):159–164. https://doi.org/10.1007/s12185-014-1611-1
20. Wu S, Zheng C, Chen S, Cai X, Shi Y, Lin B, Chen Y (2015) Subcutaneous administration of bortezomib in combination with thalidomide and dexamethasone for treatment of newly diagnosed multiple myeloma patients. Biomed Res Int 2015:927105. https://doi.org/10.1155/2015/927105
21. Mai EK, Bertsch U, Durig J, Kunz C, Haenel M, Blau I, Juhf M, Auich J, Schurich B, Muehl D, Huegel-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C,
Salwender H, Goldschmidt H (2015) Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAD) in newly diagnosed myeloma. Leukemia 29(8):1721–1729. https://doi.org/10.1038/leu.2015.80

22. Palumbo A, Gay F, Bringen S, Falcone A, Pescoata N, Callea V, Caravita T, Morabito F, Magarotto V, Ruggieri M, Avonto I, Musto P, Cascarilla N, Bruno B, Boccadoro M (2008) Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol 19(6):1160–1165. https://doi.org/10.1093/annonc/mdn018

23. Kusano Y, Terui Y, Hatake K (2015) CyBorD demonstrated its superiority to bortezomib plus dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 15:e262–e263. https://doi.org/10.1016/j.clml.2015.07.552

24. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, CJ, Ervin-Haynes A, Benboubker L (2014) Lenalidomide+low-dose chemotherapy regimens. Blood 126(23):3257

25. Beksaç M, Ozdemir E, Yagci M, Buyukkececi F, Cagiran S, Ozdugu H, Kalayoglu Besiski S, Demirkan F, Uskenet N, Kayguszuz I, Firat Tuglular T, Goker H, Ozcan MA, Cetinier M, Akyol Erikiç A, Turgut B (2011) Clinical experience with lenalidomide and dexamethasone (Len + DEX) for the treatment of patients with relapsed/refractory multiple myeloma (MM): safety and efficacy data from the Turkish compassionate use program (cup). Haematologica 96:S103–S104

26. Dimopoulos MA, Petrucci M, Foa R, Catalano J, Kropp M, Yu Z, Herbein L, Grote L, Jacques C, Palumbo A (2013) Therapy following relapse on melphalan-prednisonelenalidomide (LEN) followed by Len maintenance in elderly newly diagnosed multiple myeloma patients: efficacy and safety of second line LEN in MM-015. Haematologica 98:104–105

27. Dimopoulos MA, Roussou M, Gaviatopoulou M, Migkou M, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Christoulas D, Terpos E, Kastritis E (2012) Lenalidomide with low or intermediate dose dexamethasone in patients with relapsed or refractory myeloma. Blood 120:4028

28. Facom T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Hulin C, Cavo M, Pinto A, Weisel KC, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oral I, De La Rubia J, Qiu L, White W, Binder D, Anderson KC, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques CJ, Ervin-Haynes A, Benboubker L (2014) Lenalidomide+low-dose dexamethasone (RD) vs. melphalan-prednisonelenalidomide (MPT) in newly diagnosed multiple myeloma (NDMM) patients (PTs): the FIRST trial. Haematologica 99:220–221

29. Family L, Yang SJ, Klippe Z, Li Y, Page JH, Rodriguez R, Chao C (2015) Risk of febrile neutropenia (FN) in select myelosuppressive chemotherapy regimens. Blood 126(23):3257

30. Firatli Tuglular T, Noyan-Atalay F, Eser A, Toptas T, Pepelid F, Kaygusuza-Atangunduz I, Adiguzel C (2013) Lenalidomide in combination with low-dose dexamethasone in relapse/refractory multiple myeloma: a retrospective study. Haematologica 98:614–615

31. Firatli Tuglular T, Noyan-Atalay F, Eser A, Toptas T, Pepelid F, Kaygusuz-Atangunduz I, Adiguzel C (2013) Lenalidomide in combination with low-dose dexamethasone in relapse/refractory multiple myeloma: a retrospective study. Haematologica 98:614–615

32. Fouquet G, Tardy S, Demarquette H, Bonnet S, Gay J, Debarri H, Herbaut C, Guize S, Michel J, Perrot A, Serrier C, Miljkovic D, Aret Loiseau H, Facon T, Hulin C, Leleu X (2013) Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. Cancer 119(20):3680–3686. https://doi.org/10.1002/cncr.28274

33. Geraldes C, Pereira M, Magalhaes E, Gomes M, Afonso R, Sousa I, Teixeira A (2013) Results from real life: lenalidomide & dexamethasone in relapsed or refractory multiple myeloma outside clinical trials. Clin Lymphoma Myeloma Leuk 13:S162–S163

34. Huang SY, Yu YB, Yeh SP, Chen TY, Kuo WY, Chen CC, Wang MC, Lin HY, Lin SF, Lin TH, Hua Y, Puccio-Pick M, DeMarco D, Jacques C, Dunn P (2015) A non-interventional observational registry of patients (Pts) with relapsed/refractory multiple myeloma (RRMM) treated with lenalidomide (LEN) and dexamethasone (DEX) in Taiwan. Clin Lymphoma Myeloma Leuk 15:e299. https://doi.org/10.1016/j.clml.2015.07.607

35. Mookerjee A, Gupta R, Sharma A, Saikia T, Kumar L (2011) Lenalidomide plus low-dose dexamethasone compared with thalidomide plus low-dose dexamethasone: a randomised phase III study. Blood 118(21)

36. Moreau P, Massi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson S, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar SK, Touzeau C, Buadi F, Labach JP, Lin J, Berg D, DiBacco A, Hui AM, Richardson PG (2015) Ixazomb, an investigational oral proteasome inhibitor (PI), in combination with lenalidomide and dexamethasone (IRD), significantly extends progression-free survival (PFS) for patients (PTS) with relapsed and/or refractory multiple myeloma (RRMM): the phase 3 TOURMALINE-MM1 study (NCT01564537). Blood 126(23):727

37. Schwarz A, Fruhaufl S, Konigsmann M, Schnell R, Reeb M, Heits F, Tirier C, Prange-Krex G, Knauf W, Bachinger A, Weiligmann C, Hoppe G, Glaschneider A, Schmidt B (2014) Treatment of relapsed/refractory multiple myeloma patients with lenalidomide/dexamethasone in routine clinical practice. Oncol Res Treatment 37:291

38. Tosi P, Gamberi B, Castagnari B, Molinari AL, Savini P, Ceccolini M, Tani M, Merli A, Imola C, Cellini C, Tomassetti S, Merli F, Fattori P, Zaccaria A (2013) Lenalidomide in combination with dexamethasone in elderly patients with advanced, relapsed or refractory multiple myeloma and renal failure. Mediterr J Hematol Infect Dis 5(1):1

39. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore Jr DF, Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, Mateos MV, J, Greil R, Williams C, Gray D, Szabo Z (2016) An international multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for myeloma. LBA8025

40. Alegre A, Oriol-Rocafiguera A, Garcia-Larana J, Mateos MV, Sureda A, Martinez-Chamorro C, Cibeira MT, Aguado B, Knight R, Rossettani B (2012) Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the spanish experience. Leukemia & Lymphoma 53(9):1714–1721. https://doi.org/10.3109/10428194.2012.662643

41. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357(21):2123–2132. https://doi.org/10.1056/NEJMoa070594

42. Leleu X, Terpos E, Garcia Sanz R, Cooney J, O’Gorman P, Minarik J, Greil R, Williams C, Gray D, Szabo Z (2016) An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for...
relapsed or relapsed/refractory multiple myeloma (RR-MM). Am J Hematol 91(8):806–811. https://doi.org/10.1002/ajh.24416

43. Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Bekiac M, Spencer A, Oakervée H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, KL W, Sindahl A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):e621–631. https://doi.org/10.1056/NEJMoa1505654

44. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranina-Marnova V, Rajmies P, Suvorov A, Niesvizky R, Jakubowiak A, Miguel JFS, Ludwig H, Zojwalla N, Tonda ME, Xing B, Moreau P, Palumbo A (2014) Carfilzomib, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in patients (Pts) with relapsed multiple myeloma: interim results from ASPIRE, a randomized, open-label, multicenter phase 3 study. Blood 124(21)

45. Sun HL, Atenañu EG, Yeoboa E, Reece DE, Trudel S, Kukreti V, Masih-Khan E, Winter A, Chen C (2015) Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus lenalidomide. Leukemia and Lymphoma 56(2):407–414. https://doi.org/10.1038/410292014.915544

46. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmayer EA, Siegel D, Borrello I, Rajkumar SV, Benboubker L, Doyen C, Richard P (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma (RR-MM). Am J Hematol 91(8):806

47. Hulin C, Facon T, Rodon J, Rizzari C, Benzodami M, Schenone C, Pluznik M, Bortezomib plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27(22):3664–3670. https://doi.org/10.1200/JCO.2008.21.0948

48. Richardson PG, Schlug R, Khugaeva N, Dimopoulos M, Shirlipberg O, Kropff M, Vekemans MC, Petrucci MT, Rossieve V, Hou J, Robak T, Mateos MV, Anderson K, Esseltine M, de la Velde H, San Miguel JF (2011) Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma patients: results from the VISTA trial. Br J Haematol 153(2):212–214. https://doi.org/10.1016/j.bjha.2009.03.050

49. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zambello R, Pietrantuono G, Falcone A, Cavo M, Delforge M, Foadi A, Zambello R, Ledda A, Gentili S, Musto P, Boccadoro M, Hajek R, Palumbo A (2013) Efficacy and safety of 3 lenalidomide-based combinations in elderly newly diagnosed multiple myeloma patients: results from the phase 3 community based EMN01 trial. Haematologica 98:95–96

50. Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Weisel KC, Ocio EM, Di Raimondo F, Hasson M, Simmcock M, Miller N, Slaughter A, Peluso T, Stamas L, Zaki MH, Moreau P (2015) An updated analysis of the stratus trial (MM-010): safety and efficacy of pomalidomide plus low-dose dexamethasone (POM + LODEX) in patients (PTS) with relapsed/refractory multiple myeloma (RRMM). Blood 126(23):e288–e289. https://doi.org/10.1182/blood-2015-07-6310

51. Maciocia N, Sharpley F, Belsham E, Renshaw H, Schey S, Chene K, Sember A, Rismari A, DSA S, Streetly M, Reuben B, Jenner M, Ramasamy K, Yong K, Rabin N (2015) Outcome of pomalidomide therapy in relapsed/refractory myeloma: a UK multi-centre experience. Clin Lymphoma Myeloma Leuk 15:1066–1068. https://doi.org/10.1016/j.clml.2015.07.612

52. Palumbo A, Bringhen S, Liberiati A, Cellini C, Magavorno T, Boccadoro M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Bekiac M, Spencer A, Oakervée H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, KL W, Sindahl A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):e621–631. https://doi.org/10.1056/NEJMoa1505654

53. Hulin C, Facon T, Rodon J, Pegoibue E, Bénoubker L, Doyen C, Díab M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azais I, Decaux O, Garderet L, Mathiot C, Fontan J, Laron I, Viron JM, Moreau P (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27(22):3664–3670. https://doi.org/10.1200/JCO.2008.21.0948

54. Richardson PG, Schlug R, Khugaeva N, Dimopoulos M, Shirlipberg O, Kropff M, Vekemans MC, Petrucci MT, Rossieve V, Hou J, Robak T, Mateos MV, Anderson K, Esseltine M, de la Velde H, San Miguel JF (2011) Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol 153(2):212–221. https://doi.org/10.1111/j.1365-2605.2011.08569.x

55. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zambello R, Pietrantuono G, Falcone A, Cavo M, Delforge M, Foadi A, Zambello R, Ledda A, Gentili S, Musto P, Boccadoro M, Hajek R, Palumbo A (2013) Efficacy and safety of 3 lenalidomide-based combinations in elderly newly diagnosed multiple myeloma patients: results from the phase 3 community based EMN01 trial. Haematologica 98:95–96

56. Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Weisel KC, Ocio EM, Di Raimondo F, Hasson M, Simmcock M, Miller N, Slaughter A, Peluso T, Stemas L, Zaki MH, Moreau P (2015) An updated analysis of the stratus trial (MM-010): safety and efficacy of pomalidomide plus low-dose dexamethasone (POM + LODEX) in patients (PTS) with relapsed/refractory multiple myeloma (RRMM). Blood 126(23):e288–e289. https://doi.org/10.1182/blood-2015-07-6310

57. San Miguel J, Weiskel K, Mooreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schej S, Sonneveld P, Yu X, Stemas L, Jacques C, Zaki M, Dimopoulos M (2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 14(11):1055–1066. https://doi.org/10.1016/S1470-2045(13)70380-2

58. Cook G, Williams C, Brown JM, Caims DA, Cavaghan J, Snowden JA, Ashcroft AJ, Fletcher M, Parrish C, Snowden JA, Hunter H, Bird M, Chalmers A, O'Connor S, Drayson MT, Morris TCM (2014) High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI myeloma X relapse [intensive trial]): a randomised, open-label, phase 3 trial. Lancet Oncol 15(8):874–885. https://doi.org/10.1016/S1470-2045(14)70245-1
hydroxychloroquine with infusional cyclophosphamide, pulse dexamethasone and rapamycin in patients with relapsed or refractory multiple myeloma. Blood 124:3449

82. Radic Kristo D, Zatezalo V, Jaksic B, Acamovic B, Planinc-Peraica A, Ostojic Kolonic S (2015) Comparison of pegfilgrastim versus filgrastim after autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Bone Marrow Transplant 49(Suppl. 1):S456

83. Cerchione C, Catalano L, Pareto AE, Picardi M, Pane F (2015) Pegfilgrastim in primary prophylaxis of febrile neutropenia during chemotherapy of relapsed and refractory multiple myeloma: a real-life experience. Support Care Cancer 23(2):301–302. https://doi.org/10.1007/s00520-014-2490-y

84. Tuzzon S, Sharma M, Zhan T, Kasner M, Alpdogan O, Martinez U, Gross D, Fillocko J, Pro B, Wagner JL, Carabasi M, Flenemberg N, Weiss M (2014) Autologous stem cell mobilization with pegfilgrastim and planned plerixafor is equally effective and safer as compared with cyclophosphamide, pegfilgrastim and plerixafor. Biol Blood Marrow Transplant 20(Suppl. 2):S119. https://doi.org/10.1016/j.bbmt.2013.12.175

85. Knop S, Langer C, Engelhardt M, Muge LO, Rosler W, Reiche A, Rollig C, Hertenstein B, Gramatzki M, Bassermann F, Ostermann H, Sturm I, Ringhofer M, Schafer-Eckart K, Falk K, Liebert A, Einsele H, Bargou R (2013) Lenalidomide, adriamycin, dexamethasone (RAD) followed by risk-adjusted transplant is a novel and very effective induction regimen in newly diagnosed multiple myeloma. Onkologie 36(Suppl. 7):39

86. Knop S, Langer C, Engelhardt M, Muge LO, Roesler W, Reiche A, Rollig C, Hertenstein B, Gramatzki M, Bassermann F, Ostermann H, Sturm I, Ringhofer M, Schafer-Eckart K, Kraus S, Einsele H, Bargou R (2013) Lenalidomide, adriamycin and dexamethasone (RAD) as an induction regimen in newly diagnosed multiple myeloma-interim results from a German multicenter phase II trial. Blood 122:1987

87. Knop S, Langer C, Engelhardt M, Muge LO, Reiche A, Rosler W, Bassermann F, Hertenstein B, Sturm I, Rollig C, Ostermann H, Schafer-Eckart K, Ringhofer M, Gunther A, Junghans C, Biersack H, Strifler S, Bachinger A, Einsele H, Bargou R (2014) Response to lenalidomide, doxorubicin and dexamethasone (RAD) in newly diagnosed multiple myeloma is independent of cytogenetic risk and retained after double stem cell transplant. Blood 124:177

88. Costa LJ, Landau H, Venkata JK, Kang Y, Koehne G, Chung DJ, Lendvai N, Bentz T, Giralt S (2013) Phase 1 trial of carfilzomib + high dose melphalan conditioning regimen prior to autologous hematopoietic stem cell transplantation (AHSCST) for relapsed multiple myeloma. Blood 122:3329

89. Carlino D, Mele A, Rossini B, De Francesco R, Sibilla S, Greco G, Fina M, De Risi C, Morciano MR, Ostuni A, Pavone V (2013) Peg filgrastim versus daily granulocyte-colony stimulating factor: a comparison after autologous stem cell transplantation. Single centre experience. Haematologica 98:99

90. Kroll TM, Singavi A, Schmidt W, Eastwood D, Droby ski W, Horowitz MM, Palmer J, Pasquini MC, Rizzo JD, Saber W, Hari PN, Fenske T (2014) Safety of outpatient autologous hematopoietic cell transplantation (AUHCT) for multiple myeloma and lymphoma. Biol Blood Marrow Transplant 20(2 Suppl.):S114. https://doi.org/10.1016/j.bbmt.2013.12.166

91. Herbert KE, Gambell P, Link EK, Mouminoglu A, Wall DM, Harrison SJ, Ritchie DS, Seymour JF, Prince HM (2013) Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant 48(3):351–356. https://doi.org/10.1038/bmt.2012.145

92. Herrera JM, Huertas JF, Saavedra MA, Gomez R, Guerrero AJ, Duque JE, Urrego OM, Del Pilar Salcedo R, Martinez A (2014) Pegylated filgrastim is comparable with filgrastim as support for autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 20(2 Suppl.):S112. https://doi.org/10.1016/j.bbmt.2013.12.161

93. Aspen Pharma (2014) Summary of product characteristics: melphalan 50 mg powder and solvent for solution for injection/infusion. https://www.medicines.org.uk/emc/medicine/703. Accessed 16 October 2016

94. Partida-Sanchez S, Cockayne DA, Monard S, Jacobson EL, Oppenheimer N, Garvy B, Kusser K, Goodrich S, Howard M, Harmsen A, Randall TD, Lund FE (2001) Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat Med 7(11):1209–1216. https://doi.org/10.1038/nm1101-1209

95. Naeim F (2008) Chapter 2—principles of immunophenotyping. In: Immunopathology, pp 27–55. https://doi.org/10.1016/B978-0-12-370607-2.00002-8

96. Dunleavy K, Tay K, Wilson WH (2010) Rituximab-associated neutropenia. Semin Hematol 47(2):180–186. https://doi.org/10.1053/j.seminhematol.2010.01.009

97. Chan A, Verma S, Loibl S, Crawford J, Choi MR, Dreiling L, Vandenberg T (2012) Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Crit Rev Oncol Hematol 81(2):136–150. https://doi.org/10.1016/j.critrevonc.2011.03.003